Europe, Inc. today announced the results of phase III trial pancreatic cancer treatment

Celgene International, a Swiss pharmaceutical company, today announced the detailed results of phase III trial of the "Abraxane" metastatic pancreatic cancer therapeutics company. When used in combination with another anti-cancer drug gemcitabine Abraxane, compared with gemcitabine alone, overall survival was significantly improved (median 6.7 months for the month 8.5 months). I showed a 59% improvement, respectively, twice the 2-year survival rates and 1-year survival rate. Results of combination therapy was superior in overall response rate, etc. and progression-free survival. There was no difference between the two groups in serious toxicity. Abraxane is injectable suspension was allowed to bind to human albumin anti-cancer drug paclitaxel.